



162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 November 2000 (09.11.2000)

PCT

(10) International Publication Number
WO 00/66546 A3(51) International Patent Classification⁷: C07C 311/03,
311/04, 311/06, 311/05, 311/08, C07D 333/20, 213/81,
213/82, C07C 311/37, A61K 31/18, 31/44, 31/38[US/US]: 371 Redbud Place, Greenwood, IN 46142
(US). ZARRINMAYEH, Hamideh [US/US]; 924 Sable
Run, Carmel, IN 46032 (US). ZIMMERMAN, Dennis,
Michael [US/US]; 10343 Oak Ridge Drive, Zionsville, IN
46077 (US).

(21) International Application Number: PCT/US00/08734

(22) International Filing Date: 17 April 2000 (17.04.2000)

(74) Agents: LENTZ, Nelsen, L. et al.; Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/131,771 30 April 1999 (30.04.1999) US
60/177,566 21 January 2000 (21.01.2000) US(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BENDER, David,
Michael [US/US]; 10543 Fawn Ridge Lane, Indianapolis,
IN 46236 (US). CANTRELL, Buddy, Eugene [US/US];
1206 West 600 South, Fountaintown, IN 46130 (US).
FRAY, Andrew, Hendley [US/US]; 6862 Walnut Bend
Road, Indianapolis, IN 46254 (US). JONES, Winton,
Dennis [US/US]; 1227 East 126th Street, Carmel,
IN 46033 (US). MILLER, William, David [US/US];
7302 Trestle Way Court, Indianapolis, IN 46256 (US).
MITCHELL, David [US/US]; 8728 Santana Lane,
Indianapolis, IN 46278 (US). SIMON, Richard, Lee


Published:

— With international search report.

(88) Date of publication of the international search report:
3 May 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MONOFLUOROALKYL DERIVATIVES



WO 00/66546 A3

(57) Abstract: The present invention provides monofluoroalkyl derivatives of the formula (I) wherein: A represents SO₂, CO₂ or CONH; R^a represents (1-6C)alkyl, (2-6C)alkenyl, -(1-4C)alkyl(3-8C)cycloalkyl, or (1-4C)alkylaromatic; R^b represents H, (1-6C)alkyl, (2-6C)alkenyl, -(1-4C)alkyl(3-8C)cycloalkyl, or (1-4C)alkylaromatic; or R^a and R^b together with the carbon atoms to which they are attached form a (3-8C) saturated carbocyclic ring, a (3-8C) saturated carbocyclic ring containing a heteroatom selected from the group consisting of sulfur or oxygen, or a (5-8C) carbocyclic ring containing one double bond; R¹ represents an unsubstituted or substituted aromatic group, an unsubstituted or substituted heteroaromatic group, or an unsubstituted or substituted (5-8C)cycloalkyl group; R² represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or when A represents SO₂, a group of formula R³R⁴N in which R³ and R⁴ each independently represents (1-4C)alkyl or , together with the nitrogen atom to which they are attached form an azetidyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; or a pharmaceutically acceptable salt thereof, useful for potentiating glutamate receptor function in a mammal and thereof, useful for treating a wide variety of conditions, such as psychiatric and neurological disorder.



G00001